Background: To expedite diagnosis of serious bowel disease, efforts are required to signpost patients with high-risk symptoms to appropriate care. Community pharmacies are a recognised source of health advice regarding bowel symptoms. This study aimed to examine the effectiveness of a validated self-administered questionnaire, Jodi Lee Test (JLT), for detection, triage and referral of bowel symptoms suggestive of carcinoma, in pharmacies.
INTRODUCTION
Help seeking is considered to be the recognition of a health concern followed by a range of actions, one of which may be health service utilisation 1 . Interviews with people experiencing symptoms of bowel disease have shown that a significant proportion try to manage their own symptoms 2 , rather than consult a doctor, even when symptoms are persistent and subsequently found to be due to a life-limiting condition 3, 4 .
A number of bowel (colorectal) diseases share clinical presentations, and certain symptom profiles that are associated with serious underlying conditions such as cancer, inflammatory bowel disease or degenerative bowel conditions 5 . To improve outcomes, people need to recognise the significance of their symptoms, and general practitioners need to accurately diagnose and manage bowel diseases 6, 7 .
Faecal occult blood test screening (FOBT), available via the National Bowel Cancer
Screening Program in Australia, is limited to people turning 50, 55, 60, 65 and 74 years (the average age of a patient with colorectal cancer is 68 years) 8 . Biennial screening for those aged 50-74 began in 2015 and is due to be completed in 2020 9 . Detection of blood in bowel motions (from the FOBT) prompts recommendations for further investigations such as colonoscopy 9 . At more than 30 times the price of FOBT, colonoscopy is too expensive for a population-based screening tool 9 . Although FOBT is a valid test for bowel cancer, participation in the program is reportedly poor 10 , with barriers such as: "inconvenience of the testing process; aversion to manipulating faeces; cost; views about personal invulnerability;
and cultural beliefs and attitudes" 11 .
Community pharmacies are a recognised and common source of health advice for most Australians 12 . A survey of patients attending general practice in Australia indicated that other than general practitioners, pharmacists were identified as the most likely health professional J U S T
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who might advise about bowel symptoms 13 . On average, three or more clients per week seek symptomatic treatment for bowel symptoms 13 in each of Australia's 5450 pharmacies 14 .
Interactions between pharmacists and their symptomatic clients therefore offer an ideal opportunity to explore how pharmacy staff can complement larger-scale screening programs by identifying emerging serious illness. However, a survey of pharmacists in Australia 15 demonstrated a lack of awareness of high-risk bowel symptoms. This finding recognises the requirement for better education to understand when to refer for further medical investigation.
Research supports the use of self-administered questionnaires to help primary health care professionals, in the course of routine conversations with clients, identify cases that warrant further investigation for colorectal pathology [16] [17] [18] . The Jodi Lee Test (JLT) is a simple, short, client-completed questionnaire developed to aid consultation between pharmacy staff and clients with bowel symptoms 19 . The data provided can be reviewed by any pharmacy staff who interact with clients. For example, pharmacy assistants can use the data to determine when the client should be referred to the pharmacist, and pharmacists to determine when referral to a general practitioner is required 19 . The key items in the JLT indicating the need for referral for general practitioner assessment are the client's symptom(s), symptom duration and history of gastrointestinal disease 19 . The JLT demonstrates high sensitivity (100%) and modest specificity (65%) for identification and triage of symptoms of bowel disease when compared to a validated tool, the Patient Consultation Questionnaire (PCQ) 19 . By comparison, the PCQ assists general practitioners in prioritising referrals for colorectal conditions, and has high sensitivity for serious colorectal pathologies 5, 20 .
The purpose of this study was to examine the feasibility and effectiveness of use of the JLT as a guide to pharmacy staff to identify clients with bowel symptoms warranting general practitioner assessment ('referral').
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MATERIALS AND METHODS
Ethical approval was granted by the [name deleted for blind review] Human Research Ethics
Committee (HR19_2013). This study used a prospective pre-post design in community pharmacies in Western Australia, and was conducted from May 2013 to March 2014. Prior to commencement of the intervention, data were collected concerning the usual practice (UP) of pharmacy staff dealing with clients seeking assistance for bowel symptoms. Following the UP phase, the JLT was introduced to guide the pharmacy staff in their interaction with the client (the intervention). These phases are described below. The value of the JLT was assessed between the two phases of the study by comparing the referrals to, and subsequent contact by the client with, the clients' general practitioner for those considered to have signs of potentially serious disease.
Sample size
The personalised data collection and client follow-up warranted a manageable, localised sample for this feasibility trial, compared to large-scale screening programs. The previous development and validation study reported that 55% of clients who were screened using the JLT were indicated as requiring general practitioner referral 19 . For the purposes of this study, it was conservatively assumed the referral rate would reduce to approximately 35% after the pharmacist reviewed the completed questionnaire, communicated with the client, and applied his/her clinical judgement, in line with the protocol for use of the JLT. In the previous study, approximately 10% of eligible clients were referred to their general practitioner when the pharmacist was not using a decision support aid 13 . In order to detect a difference of this magnitude in the proportion of clients referred for further investigation 'using' versus 'not using' the decision-support aid (35% vs. 10%) with power=90% and α=0.05, 65 participants would be required in each arm of the trial. Allowing for an estimated 20% loss to follow-up, this number was adjusted to n=82 in each arm. Conservatively assuming that each pharmacy
would recruit at least one participant each week, i.e. a one-in-three recruitment rate 15 , it was estimated that 20 pharmacies would be required to complete the study within the proposed timeframe.
A convenience sample of 21 pharmacies in Western Australia was recruited to take part in the study: 17 in the Perth metropolitan area and four from regional towns. The locations of the pharmacies were selected to represent a range of socioeconomic areas. Data collection commenced with the UP phase; however, these data were not collected from two pharmacies that joined the study prior to the commencement of the intervention. Written consent was gained from all staff members of the pharmacies, including pharmacy assistants, pharmacists, 
Usual-Practice Phase
Pharmacy staff recruited consecutive clients seeking advice for bowel symptoms or seeking medicines normally used to treat diarrhoea, constipation or haemorrhoids. Participating clients were to be aged at least 18 years and able to give written informed consent to take part
in the study, which included contact by the researcher for follow-up after their pharmacy visit.
The pharmacy staff continued their usual service in managing clients' bowel symptoms.
Consultations with consenting clients were documented by the pharmacists, recording the clients' reported symptom(s), medication purchased, referrals for further investigation, and reasons for referrals. The pharmacies aimed to recruit and follow-up a total of 82 participants for this phase over a period of 12 weeks. 
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RESULTS
Baseline
One hundred and ninety-one pharmacy staff, comprising 122 pharmacy assistants, 62
pharmacists and seven pre-registered pharmacists, completed the baseline survey. The mean age for pharmacy assistants was 28 years (range: 15-62 years), and 32 years (range: 22-56 years) for pharmacists and pre-registered pharmacists. Pharmacists and pre-registered pharmacists had around 10 years' work experience in pharmacy, while the pharmacy assistants recorded approximately six years. Twenty-one percent of the pharmacy assistants were tertiary educated, and 44% had completed year 12 or equivalent. Self-reported data from the participating pharmacies revealed pharmacy assistants typically gathered information about clients' symptoms, history and lifestyle. The pharmacists offered advice on managing symptoms and lifestyle, and provided further information about the symptoms, medication and referral to a general practitioner.
Assessment of the JLT Intervention
Eighty-four clients were recruited from 19 pharmacies and followed up over 12 weeks in the UP Phase (Table 1) ; these comprised 60 (71%) females and 24 (29%) males. Twenty-one were lost to follow-up, and seven were excluded on the basis of age.
Only 19 of the 21 selected pharmacies recruited clients for JLT phase. Eighty clients were recruited and followed up over 20 weeks in the Intervention Phase, comprising 54 (68%) females and 26 (33%) males. Fourteen were lost to follow-up.
Fifty of the 80 clients (63%) were initially identified on self-completion of the JLT as meriting referral to a general practitioner. However, during the ensuing consultation, only 30 (38%) were confirmed by pharmacists as warranting referral. Common reasons why the pharmacists did not refer cases indicated by the JLT as warranting further consideration were that the client's general practitioner was aware of the symptoms for which he/she was seeking J U S T
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advice, or that the presenting symptom was an obvious side effect of a prescription medication the client was taking.
The intervention was associated with a significantly higher referral rate during the Intervention Phase compared to the UP Phase: 38% vs 20% ( Table 1 Twenty-one (45%) reported using the JLT when consulting clients with bowel symptoms.
Thirty (64%) of the pharmacy staff agreed that the JLT could be incorporated in the pharmacy, and 33 (70%) indicated they would use the JLT in future when managing clients with bowel symptoms.
The effectiveness of JLT is illustrated by the following quotations from pharmacy staff:
"Effective way to establishing client needs and current bowel symptoms" (pharmacy assistant).
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"Confirming 'red flags' for early detection of bowel signs and symptoms that warranted referral for medical advice" (pharmacist).
"Establishing consistent practice in the pharmacy" (pharmacist).
"Providing timely, effective professional advice and information to clients, including advice about consulting a general practitioner" (pharmacist).
"Helpful in reinforcing the case of referral when the client was initially hesitant to see the general practitioner" (pharmacist).
Additional feedback related to the JLT being simple and quick to use, easy to understand by the client, non-invasive, easier for clients who feel embarrassed to discuss their bowel symptoms, and a good checklist approach for quick response in a busy pharmacy. In critiquing the tool, some stated the study protocol booklet format was time consuming and a deterrent to the recruitment process. Reasons given by staff for not using the JLT were largely logistical, including workflow, lack of private consultation space in their pharmacy, and few clients perceived as eligible. Other conditions for which the pharmacy staff would accept a JLT-like questionnaire were urinary tract infections, asthma, vaginal candidiasis, cough, chronic pain, kidney problems, headaches, and upper gastro-intestinal symptoms.
DISCUSSION
This prospective study supports the use of a brief self-administered questionnaire, the JLT, as a clinical decision tool for pharmacy staff to identify symptoms that might require medical investigation. It also serves as a written referral to the general practitioner. Capitalising on the personalised nature and convenience of pharmacist-client consultations, this intervention has the potential to complement larger-scale bowel cancer screening programs. Staff in the pharmacy were made aware of people who were presenting with symptoms that may require medical assessment. The client and the pharmacist were afforded the opportunity to discuss these in detail, and in some cases, referral was considered unnecessary. A reasonable assumption was made by the pharmacists that if a client had recently consulted a general practitioner, the general practitioner was almost certainly aware of the symptom(s) and was managing the client appropriately. Other clinical situations may have also overridden a pharmacist's decision to refer a client.
In cases where referral was warranted, the participants were advised of the need for a medical consultation and given a referral letter to take to the general practitioner. Use of the JLT resulted in 38% of clients being referred to their general practitioner, compared to 20% during UP. This result is in line with studies reporting that health questionnaires completed by patients frequently captured more positive symptoms than elicited during consultation 21, 22 .
Our empirical evidence also indicates a greater proportion of the clients accepted referral.
This finding is consistent with other studies that reported increased general practitioner consultation after being encouraged by a pharmacist 13, 23 .
The concept of applying a decision-support tool in pharmacy practice was novel to our participating pharmacy staff, and although it may not be applicable to all practice settings or situations, the JLT shows promise in guiding management of bowel symptoms. In particular, the documentation of completed JLT and written referral, produced for cases warranting referral appears to hold value for clients, evidenced by their uptake of recommendations to
consult their general practitioner. Alternatively, for situations able to be managed in the pharmacy, the JLT highlights to the pharmacy staff member the presenting symptoms and their significance.
As established in the baseline phase, the first point of contact for the client was commonly the pharmacy assistant. As such, prompting pharmacy assistants' use of a simple, structured assessment tool can benefit the pharmacy workflow in triaging clients to be referred to the pharmacist and supporting the provision of non-prescription medicines; these are recognised roles for pharmacy assistants in Australia 24 .
Most of the pharmacy staff found the JLT to be a simple and effective assessment guide for management of bowel symptoms, and reported that clients managed to complete the questions unassisted. As such, its deployment did not burden pharmacy staff. The majority of burden related to client recruitment and consent for research purposes (follow-up).
Although a randomised control trial (RCT) is the ideal design to test pharmacy-led interventions; it was not feasible in this case for several reasons. Firstly, one of the objectives of the study was to identify if a change in referral practices of pharmacists could be achieved by introducing to them a structured questionnaire approach (the JLT) for these clients. Once the JLT is used for a particular client in a pharmacy, it would not be practical to revert to UP for a subsequent client. A cluster design where pharmacies applied only UP or the JLT would have avoided the issue of randomising clients, but differences between practices in terms of staffing and demographic profile may have confounded the analysis. For these reasons, a prepost design was considered the most appropriate.
The study protocol was not consistently applied in some pharmacies, highlighting the challenges of research in a naturalistic setting. Although the researcher closely monitored the study progress, adherence to the study protocol by individual staff was not able to be controlled. Ideally, this trial would have also included client feedback on the JLT to J U S T A C C E P T E D supplement developmental research in its design 19 , and validation of client outcomes using general practice data. Further research on the acceptability of the JLT directly from the client's perspective is required to determine their expectations of pharmacy services when presenting with bowel symptoms. Though a practising GP was involved in the design and validation stage of JLT 19 , no GPs to whom the clients were referred to, were asked to give feedback on the written referral that was given to clients whose symptoms warranted further medical consultation. Loss to follow-up is also recognised as a limitation in outcomesfocussed research.
Our findings suggest potential for wider application of the JLT as an optional practiceenhancing guide to over-the-counter consultations in the community pharmacy setting. There 
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CONCLUSIONS
The JLT was found to be an acceptable assessment tool for the triage of bowel symptoms in a pharmacy setting. Its effectiveness was demonstrated by prompting a higher rate of referrals in those who would benefit from a general practitioner investigation, a higher rate of uptake of recommendations for referral and more clinical diagnoses compared to the usual model of consultation. As such, the JLT shows promise as an effective decision-making aid in the pharmacy to triage clients at higher risk of bowel cancer. 
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